Metsera, A Wholly Owned Subsidiary Of Pfizer
Clinical trials sponsored by Metsera, A Wholly Owned Subsidiary Of Pfizer, explained in plain language.
-
New Two-Drug combo enters human testing for obesity and diabetes
Disease control Recruiting nowThis early-stage study is testing the safety and how the body processes a new two-drug combination (MET233 and MET097) for weight management. It will enroll 132 adults with obesity or who are overweight, including some with type 2 diabetes. The main goal is to see if the treatmen…
Phase: PHASE1, PHASE2 • Sponsor: Metsera, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Major trial tests new weekly shot to fight obesity
Disease control Recruiting nowThis study is testing a new weekly injection called MET097 to see how well it helps people with obesity or overweight lose weight and improve related health measures. It will involve about 3,500 adults who have weight-related health issues like high blood pressure or sleep apnea,…
Phase: PHASE3 • Sponsor: Metsera, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC